NCT00737776View on ClinicalTrials.gov

Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes

CompletedOBSERVATIONAL
Enrollment

1,068

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 30

Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Trial Locations (1)

137-920

Novo Nordisk Investigational Site, Seoul

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY